A critical overview on ticagrelor in acute coronary syndromes

E. P. Navarese; Antonino Maria Tommaso Buffon; M. Kozinski; K. Obonska; M. Rychter; V. Kunadian; D. Austin; S. De Servi; A. Sukiennik; J. Kubica

doi:10.1093/qjmed/hcs187

A critical overview on ticagrelor in acute coronary syndromes

E. P. Navarese
, Antonino Maria Tommaso Buffon
, M. Kozinski
, K. Obonska
, M. Rychter
, V. Kunadian
, D. Austin
, S. De Servi
, A. Sukiennik
, J. Kubica

Nicolaus Copernicus University in Toruń
Newcastle upon Tyne Hospitals NHS Foundation Trust
Civic Hospital

Risultato della ricerca: Contributo in rivista › Articolo

13 Citazioni (Scopus)

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

Lingua originale	Inglese
pagine (da-a)	105-115
Numero di pagine	11
Rivista	QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume	106
DOI	https://doi.org/10.1093/qjmed/hcs187
Stato di pubblicazione	Pubblicato - 2013

Keywords

Acute Coronary Syndrome
Adenosine
Aspirin
Double-Blind Method
Female
Humans
Male
Platelet Aggregation Inhibitors
Purinergic P2 Receptor Antagonists
Randomized Controlled Trials as Topic
Risk Assessment
Ticlopidine
Treatment Outcome

Accesso al documento

10.1093/qjmed/hcs187

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{328c400e5c87490eb7398064b924188d,

title = "A critical overview on ticagrelor in acute coronary syndromes",

abstract = "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.",

keywords = "Acute Coronary Syndrome, Adenosine, Aspirin, Double-Blind Method, Female, Humans, Male, Platelet Aggregation Inhibitors, Purinergic P2 Receptor Antagonists, Randomized Controlled Trials as Topic, Risk Assessment, Ticlopidine, Treatment Outcome, Acute Coronary Syndrome, Adenosine, Aspirin, Double-Blind Method, Female, Humans, Male, Platelet Aggregation Inhibitors, Purinergic P2 Receptor Antagonists, Randomized Controlled Trials as Topic, Risk Assessment, Ticlopidine, Treatment Outcome",

author = "Navarese, \{E. P.\} and Buffon, \{Antonino Maria Tommaso\} and M. Kozinski and K. Obonska and M. Rychter and V. Kunadian and D. Austin and \{De Servi\}, S. and A. Sukiennik and J. Kubica",

year = "2013",

doi = "10.1093/qjmed/hcs187",

language = "English",

volume = "106",

pages = "105--115",

journal = "QJM-AN INTERNATIONAL JOURNAL OF MEDICINE",

issn = "1460-2725",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - A critical overview on ticagrelor in acute coronary syndromes

AU - Navarese, E. P.

AU - Buffon, Antonino Maria Tommaso

AU - Kozinski, M.

AU - Obonska, K.

AU - Rychter, M.

AU - Kunadian, V.

AU - Austin, D.

AU - De Servi, S.

AU - Sukiennik, A.

AU - Kubica, J.

PY - 2013

Y1 - 2013

N2 - Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

AB - Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

KW - Acute Coronary Syndrome

KW - Adenosine

KW - Aspirin

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Platelet Aggregation Inhibitors

KW - Purinergic P2 Receptor Antagonists

KW - Randomized Controlled Trials as Topic

KW - Risk Assessment

KW - Ticlopidine

KW - Treatment Outcome

KW - Acute Coronary Syndrome

KW - Adenosine

KW - Aspirin

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Platelet Aggregation Inhibitors

KW - Purinergic P2 Receptor Antagonists

KW - Randomized Controlled Trials as Topic

KW - Risk Assessment

KW - Ticlopidine

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/57496

U2 - 10.1093/qjmed/hcs187

DO - 10.1093/qjmed/hcs187

M3 - Article

SN - 1460-2725

VL - 106

SP - 105

EP - 115

JO - QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

JF - QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

ER -

A critical overview on ticagrelor in acute coronary syndromes

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo